| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014 | 2995 | 2014 |
| Clinical implications of PTEN loss in prostate cancer T Jamaspishvili, DM Berman, AE Ross, HI Scher, AM De Marzo, JA Squire, ... Nature Reviews Urology 15 (4), 222-234, 2018 | 636 | 2018 |
| Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes CM Heaphy, AP Subhawong, SM Hong, MG Goggins, EA Montgomery, ... The American journal of pathology 179 (4), 1608-1615, 2011 | 611 | 2011 |
| Proposed morphologic classification of prostate cancer with neuroendocrine differentiation JI Epstein, MB Amin, H Beltran, TL Lotan, JM Mosquera, VE Reuter, ... The American journal of surgical pathology 38 (6), 756-767, 2014 | 587 | 2014 |
| PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients TL Lotan, B Gurel, S Sutcliffe, D Esopi, W Liu, J Xu, JL Hicks, BH Park, ... Clinical cancer research 17 (20), 6563-6573, 2011 | 409 | 2011 |
| Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma HL Tan, A Sood, HA Rahimi, W Wang, N Gupta, J Hicks, S Mosier, ... Clinical cancer research 20 (4), 890-903, 2014 | 366 | 2014 |
| Long interspersed element-1 protein expression is a hallmark of many human cancers N Rodić, R Sharma, R Sharma, J Zampella, L Dai, MS Taylor, RH Hruban, ... The American journal of pathology 184 (5), 1280-1286, 2014 | 323 | 2014 |
| The role of lineage plasticity in prostate cancer therapy resistance H Beltran, A Hruszkewycz, HI Scher, J Hildesheim, J Isaacs, EY Yu, ... Clinical cancer research 25 (23), 6916-6924, 2019 | 312 | 2019 |
| The placental gene PEG10 promotes progression of neuroendocrine prostate cancer S Akamatsu, AW Wyatt, D Lin, S Lysakowski, F Zhang, S Kim, C Tse, ... Cell reports 12 (6), 922-936, 2015 | 283 | 2015 |
| Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation A Lucioni, GT Bales, TL Lotan, DS McGehee, SP Cook, DE Rapp BJU international 101 (3), 366-370, 2008 | 256 | 2008 |
| NCCN Guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ... Journal of the National Comprehensive Cancer Network 20 (12), 1288-1298, 2022 | 244 | 2022 |
| Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ... Journal of the National Comprehensive Cancer Network 21 (10), 1067-1096, 2023 | 241 | 2023 |
| The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer JI Epstein, MB Amin, SW Fine, F Algaba, M Aron, DE Baydar, AL Beltran, ... Archives of pathology & laboratory medicine 145 (4), 461-493, 2021 | 236 | 2021 |
| ERG gene rearrangements are common in prostatic small cell carcinomas TL Lotan, NS Gupta, W Wang, A Toubaji, MC Haffner, A Chaux, JL Hicks, ... Modern pathology 24 (6), 820-828, 2011 | 236 | 2011 |
| A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer TU Ahearn, A Pettersson, EM Ebot, T Gerke, RE Graff, CL Morais, ... Journal of the National Cancer Institute 108 (2), djv346, 2016 | 217 | 2016 |
| CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD … ES Antonarakis, P Isaacsson Velho, W Fu, H Wang, N Agarwal, ... JCO precision oncology 4, 370-381, 2020 | 212 | 2020 |
| Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations ES Antonarakis, F Shaukat, PI Velho, H Kaur, E Shenderov, DM Pardoll, ... European urology 75 (3), 378-382, 2019 | 184 | 2019 |
| PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy TL Lotan, FLF Carvalho, SB Peskoe, JL Hicks, J Good, HL Fedor, ... Modern Pathology 28 (1), 128-137, 2015 | 178 | 2015 |
| MSH2 loss in primary prostate cancer LB Guedes, ES Antonarakis, MT Schweizer, N Mirkheshti, F Almutairi, ... Clinical cancer research 23 (22), 6863-6874, 2017 | 164 | 2017 |
| Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials MP Deek, K Van der Eecken, P Sutera, RA Deek, V Fonteyne, AA Mendes, ... Journal of clinical oncology 40 (29), 3377-3382, 2022 | 163 | 2022 |
